<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654338</url>
  </required_header>
  <id_info>
    <org_study_id>3592</org_study_id>
    <nct_id>NCT04654338</nct_id>
  </id_info>
  <brief_title>2 Ablative RadioTherapy Treatments for Prostate Cancer</brief_title>
  <acronym>EARTH</acronym>
  <official_title>Electively Combining Two Ablative RadioTherapy Treatments for Favorable Risk Prostate Cancer Patients (EARTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Favorable-risk prostate cancer represent a large proportion of patients diagnosed with&#xD;
      prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these&#xD;
      patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative&#xD;
      body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects,&#xD;
      less cost and improved system capacity without sacrificing excellent cancer control rates. By&#xD;
      the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be&#xD;
      superior to standard external beam radiation. While two HDR fractions appear to optimize&#xD;
      patient convenience and outcomes while minimizing costs, we wanted to determine the&#xD;
      tolerability of combining one MR-guided HDR treatment with one SABR treatment to further&#xD;
      reduce HDR resource use while maintaining favourable treatment outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-Treatment:&#xD;
&#xD;
      Planning CT and mpMRI imaging for SABR TRUS with biopsy and insertion of Gold Seed Fiducial&#xD;
      Markers Biobanking of urine, blood and biopsy tissue (as per REB#079-2006 Odette Cancer&#xD;
      Centre (OCC) biobanking protocol)&#xD;
&#xD;
      Stereotactic Ablative Body Radiation (SABR):&#xD;
&#xD;
      13.5Gy x 1 to whole prostate + 1cm seminal vesicles 2 weeks post-planning, treatment will be&#xD;
      delivered as per standard treatment protocols on SABR-compatible linear accelerator with a&#xD;
      six-degree of freedom couch. Cone-beam CT imaging will be performed using the implanted&#xD;
      fiducials to set up each treatment. All dosimetric parameters will be recorded.&#xD;
&#xD;
      Inter-treatment (approx 1 week post-SABR):&#xD;
&#xD;
      Planning mpMRI and TRUS imaging for HDR Biobanking of urine and blood (as per REB#079-2006&#xD;
      OCC biobanking protocol)&#xD;
&#xD;
      HDR brachytherapy:&#xD;
&#xD;
      13.5 Gy x 1 to the prostate, &lt;20 Gy to DIL Approx 2-3 weeks post-SABR, the HDR dose&#xD;
      prescription of 13.5 Gy to the whole gland and &lt;20 Gy to MRI visible lesion will be delivered&#xD;
      in one fraction, assuming that dose constraints to critical organs can be met. All dosimetric&#xD;
      parameters will be recorded&#xD;
&#xD;
      Patient Assessments / Follow-up Time zero will be the date of SABR treatment. Baseline&#xD;
      rectal, urinary and sexual function will be recorded prior to treatment. Acute toxicities&#xD;
      will be assessed at 6, 12 and 24 weeks and late toxicities will be assessed at month 9, 24&#xD;
      and every 6 months until year 5 using the Common Terminology Criteria Adverse Events, V 4.0.&#xD;
      Bloodwork (PSA and testosterone) and International Prostate Symptom Score (IPSS) evaluations&#xD;
      will be performed at baseline week 6, month 3, 6, 9 and 24, and every 6 months until year 5.&#xD;
      QOL using the Expanded Prostate Cancer Index Composite (EPIC), EQ-5D and PORPUS&#xD;
      questionnaires will be obtained at baseline, month 3, 6, 9 and 24 and every 6 months until&#xD;
      year 5. Post-treatment biobanking will be done at 13 and 52 weeks (as per REB#079-2006 OCC&#xD;
      biobanking protocol)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicities</measure>
    <time_frame>6 months</time_frame>
    <description>Acute GU and GI toxicities according to the NCI CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>Late GU and GI toxicities according to the NCI CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life changes utilizing the Expanded Prostate Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical failure and PSA kinetics using PSA response rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SABR + HDR</intervention_name>
    <description>One SABR treatment + one HDR brachytherapy treatment</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Favorable risk disease defined as either:&#xD;
&#xD;
               -  Low risk disease: T1-T2c, grade group 1, PSA &lt; 10 ng/ml or&#xD;
&#xD;
               -  Favorable intermediate risk disease: One of T2c, grade group 2, or PSA 10-20&#xD;
                  ng/ml. Patients cannot have percent core positivity &gt; 50%&#xD;
&#xD;
          -  Prostate volume &lt; 60 cc as determined by US, CT or MRI&#xD;
&#xD;
          -  Ability to undergo MR imaging&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented nodal or distant metastases&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Previous transurethral resection of prostate, previous prostatectomy or HIFU&#xD;
&#xD;
          -  Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors permitted&#xD;
&#xD;
          -  Poor baseline urinary function defined as International Prostate Symptom Score (IPSS)&#xD;
             &gt;15&#xD;
&#xD;
          -  Contra-indication to radical prostate radiotherapy e.g. connective tissue disease or&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  Significant medical co-morbidity rendering patient unsuitable for general anaesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merrylee McGuffin, MSc</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>85454</phone_ext>
    <email>Merrylee.Mcguffin@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Loblaw, MD, FRCPC</last_name>
      <phone>416-480-4806</phone>
      <email>Andrew.Loblaw@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Merrylee McGuffin, MSc, MRT(T)</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85454</phone_ext>
      <email>Merrylee.Mcguffin@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Andrew Loblaw</investigator_full_name>
    <investigator_title>GU Radiation Oncology Site Group Lead</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

